Page 360 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 360
Late Breaker ePosters (Cont.)
LP38 EFFICACY AND SAFETY OF IFN-FREE ANTIVIRAL
THERAPY IN PATIENTS WITH HCV RECURRENCE AFTER
LIVER TRANSPLANTATION: REAL-LIFE EXPERIENCE
FROM AUSTRIA
Sandra Beinhardt *, Clarissa Freissmuth, Ramona Al-Zoairy,
Karin Kozbial, Stephanie Hametner, Rafael Stern, Rudolf Stauber ,
Andreas Maieron, Katharina Staufer, Michael Strasser, Heinz Zoller,
Ivo Graziadei, Wolfgang Vogel, Markus Peck-Radosavljevic,
Michael Trauner, Peter Ferenci, Harald Hofer, Austria
LP39 IMPLICATIONS OF BASELINE HCV RNA LEVEL AND
INTRAPATIENT VIRAL LOAD VARIABILITY ON OBV/PTV/R +
DSV 12-WEEK TREATMENT OUTCOMES
Robert S. Brown*, Massimo Puoti, Curtis Cooper, David L. Wyles,
Thomas E. Sepe, Ronald G. Nahass, Martin King, Eoin Coakley,
Barbara H. McGovern, Jordan J. Feld, The United States
LATE BREAKER ePOSTERS LP40 SB 9200, A NOVEL IMMUNOMODULATOR FOR PATIENTS
WITH VIRAL HEPATITIS: PHASE 1 MAD STUDY IN PATIENTS
WITH HEPATITIS C VIRUS (HCV) INFECTION
Alex Thompson*, Stuart Roberts, Wendy Cheng, Peter Angus,
Kumar Visvanathan, Radhakrishnan Iyer, Murray Barclay, Australia
LP41 LIVER FIBROSIS EPIDEMIOLOGY REVISITED USING
SOFTWARE COMBINED BIOMARKER: PROOF OF
CONCEPT USING 1,081,658 CENTRALIZED FIBROTEST (FT)
PRESCRIPTIONS
Thierry Poynard*, Olivier Deckmyn, Joe Sebastian, Mona Munteanu,
Yen Ngo, Fabienne Drane, Janet Queen, Jean Marie Castille, France
LP42 SAFETY AND EFFICACY OF NOVEL ANTIVIRALS IN KIDNEY
TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C
VIRUS (HCV) INFECTION
Ming V. Lin*, Meghan E. Sise, Martha Pavlakis, Jasmine M. Hanifi,
Anna E. Rutherford, Nahel Elias, Eliot C. Heher, Michael P. Curry,
Leonardo V. Riella, The United States
LP43 WHAT IS REQUIRED FOR CONTROL AND ELIMINATION OF
HEPATITIS B GLOBALLY?
Shevanthi Nayagam*, Mark Thursz, Stefan Wiktor, Daniel Low-Beer,
Timothy Hallett, The United Kingdom
360 The International Liver Congress™ 2015 • ILC Programme
LP38 EFFICACY AND SAFETY OF IFN-FREE ANTIVIRAL
THERAPY IN PATIENTS WITH HCV RECURRENCE AFTER
LIVER TRANSPLANTATION: REAL-LIFE EXPERIENCE
FROM AUSTRIA
Sandra Beinhardt *, Clarissa Freissmuth, Ramona Al-Zoairy,
Karin Kozbial, Stephanie Hametner, Rafael Stern, Rudolf Stauber ,
Andreas Maieron, Katharina Staufer, Michael Strasser, Heinz Zoller,
Ivo Graziadei, Wolfgang Vogel, Markus Peck-Radosavljevic,
Michael Trauner, Peter Ferenci, Harald Hofer, Austria
LP39 IMPLICATIONS OF BASELINE HCV RNA LEVEL AND
INTRAPATIENT VIRAL LOAD VARIABILITY ON OBV/PTV/R +
DSV 12-WEEK TREATMENT OUTCOMES
Robert S. Brown*, Massimo Puoti, Curtis Cooper, David L. Wyles,
Thomas E. Sepe, Ronald G. Nahass, Martin King, Eoin Coakley,
Barbara H. McGovern, Jordan J. Feld, The United States
LATE BREAKER ePOSTERS LP40 SB 9200, A NOVEL IMMUNOMODULATOR FOR PATIENTS
WITH VIRAL HEPATITIS: PHASE 1 MAD STUDY IN PATIENTS
WITH HEPATITIS C VIRUS (HCV) INFECTION
Alex Thompson*, Stuart Roberts, Wendy Cheng, Peter Angus,
Kumar Visvanathan, Radhakrishnan Iyer, Murray Barclay, Australia
LP41 LIVER FIBROSIS EPIDEMIOLOGY REVISITED USING
SOFTWARE COMBINED BIOMARKER: PROOF OF
CONCEPT USING 1,081,658 CENTRALIZED FIBROTEST (FT)
PRESCRIPTIONS
Thierry Poynard*, Olivier Deckmyn, Joe Sebastian, Mona Munteanu,
Yen Ngo, Fabienne Drane, Janet Queen, Jean Marie Castille, France
LP42 SAFETY AND EFFICACY OF NOVEL ANTIVIRALS IN KIDNEY
TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C
VIRUS (HCV) INFECTION
Ming V. Lin*, Meghan E. Sise, Martha Pavlakis, Jasmine M. Hanifi,
Anna E. Rutherford, Nahel Elias, Eliot C. Heher, Michael P. Curry,
Leonardo V. Riella, The United States
LP43 WHAT IS REQUIRED FOR CONTROL AND ELIMINATION OF
HEPATITIS B GLOBALLY?
Shevanthi Nayagam*, Mark Thursz, Stefan Wiktor, Daniel Low-Beer,
Timothy Hallett, The United Kingdom
360 The International Liver Congress™ 2015 • ILC Programme
